We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.68B
AUM Growth
+$199M
Cap. Flow
-$1.42B
Cap. Flow %
-30.22%
Top 10 Hldgs %
50.13%
Holding
119
New
17
Increased
19
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$29M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$27.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$27M
4
AMED
Amedisys
AMED
+$25.5M
5
RVMD icon
Revolution Medicines
RVMD
+$22.6M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$52.3M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$48.8M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$39.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$36.6M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 68.03%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMSW icon
76
NewAmsterdam Pharma Warrant
NAMSW
$87.5M
$194K ﹤0.01%
92,787
– –
BFLY.WS
77
DELISTED
Butterfly Network Inc Warrants
BFLY.WS
$173K ﹤0.01%
733,333
– –
QSIAW
78
DELISTED
Quantum-Si Inc Warrant
QSIAW
$76.7K ﹤0.01%
333,333
– –
TOIIW
79
The Oncology Institute Warrant
TOIIW
$6.21M
$34.9K ﹤0.01%
1,250,000
– –
SLGCW
80
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$30K ﹤0.01%
120,000
– –
SIEN
81
DELISTED
Sientra, Inc.
SIEN
$29.3K ﹤0.01%
10,000
– –
NUVB.WS
82
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$27.6K ﹤0.01%
166,666
– –
TLSIW icon
83
TriSalus Life Sciences Warrant
TLSIW
$27.8M
$14K ﹤0.01%
333,333
– –
SRZNW icon
84
Surrozen Inc Warrant
SRZNW
$9.2K ﹤0.01%
166,666
– –
MTACU
85
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$10 ﹤0.01%
1
– –
BLUE
86
DELISTED
bluebird bio
BLUE
– –
-108,750
Closed -$6.92M
CSTL icon
87
Castle Biosciences
CSTL
$729M
– –
-272,135
Closed -$6.18M
EOLS icon
88
Evolus
EOLS
$361M
– –
-3,569,000
Closed -$30.2M
IOVA icon
89
Iovance Biotherapeutics
IOVA
$2.25B
– –
-1,831,607
Closed -$11.2M
KRYS icon
90
Krystal Biotech
KRYS
$10.1B
– –
-311,949
Closed -$25M
MIRM icon
91
Mirum Pharmaceuticals
MIRM
$7.1B
– –
-2,032,335
Closed -$48.8M
PACB icon
92
Pacific Biosciences
PACB
$419M
– –
-650,000
Closed -$7.53M
PCVX icon
93
Vaxcyte
PCVX
$8.04B
– –
-295,000
Closed -$11.1M
TARS icon
94
Tarsus Pharmaceuticals
TARS
$2.5B
– –
-1,156,032
Closed -$14.5M
VERA icon
95
Vera Therapeutics
VERA
$2.71B
– –
-1,300,000
Closed -$10.1M
ITCI
96
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-734,000
Closed -$39.7M
NVTA
97
DELISTED
Invitae Corporation
NVTA
– –
-9,274,707
Closed -$12.5M
RAIN
98
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-227,393
Closed -$1.99M
ISEE
99
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,504,578
Closed -$36.6M
BLU
100
DELISTED
BELLUS Health Inc.
BLU
– –
-3,581,000
Closed -$25.8M
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2023 Portfolio in Review

As of Q2 2023, Deerfield Management held 119 positions worth $4.68B, up 4.4% from $4.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deerfield Management withdrew a net $1.42B in Q2 2023, closing 18 positions and reducing 10 holdings. Its most notable exit was Mirum Pharmaceuticals, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intercept Pharmaceuticals, Inc. worth $23M.

  • Deerfield Management's largest Q2 2023 buy was Intercept Pharmaceuticals, Inc.: 2,077,893 shares worth $23M.
  • Deerfield Management added most to Amedisys in Q2 2023, an estimated $25.5M increase.
  • Deerfield Management's biggest Q2 2023 reduction was Neurocrine Biosciences, cutting an estimated $52.3M.
  • Deerfield Management fully exited Mirum Pharmaceuticals in Q2 2023, selling an estimated $48.8M.
  • Deerfield Management's ten largest holdings make up 50% of its $4.68B portfolio in Q2 2023.
  • Deerfield Management opened 17 new positions and closed 18 in Q2 2023.
  • Deerfield Management's portfolio value rose 4.4% quarter-over-quarter to $4.68B.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.